{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,18]],"date-time":"2026-11-18T04:10:09Z","timestamp":1794975009202,"version":"4.9.1"},"reference-count":249,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2021,2,3]],"date-time":"2021-02-03T00:00:00Z","timestamp":1612310400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2021,2,3]],"date-time":"2021-02-03T00:00:00Z","timestamp":1612310400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Rev Drug Discov"],"published-print":{"date-parts":[[2021,4]]},"DOI":"10.1038\/s41573-020-00135-8","type":"journal-article","created":{"date-parts":[[2021,2,3]],"date-time":"2021-02-03T08:09:18Z","timestamp":1612339758000},"page":"309-325","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2032,"title":["Trends in peptide drug discovery"],"prefix":"10.1038","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1996-4646","authenticated-orcid":false,"given":"Markus","family":"Muttenthaler","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2308-2200","authenticated-orcid":false,"given":"Glenn F.","family":"King","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7030-2288","authenticated-orcid":false,"given":"David J.","family":"Adams","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7454-6522","authenticated-orcid":false,"given":"Paul F.","family":"Alewood","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,2,3]]},"reference":[{"key":"135_CR1","doi-asserted-by":"publisher","first-page":"2149","DOI":"10.1021\/ja00897a025","volume":"85","author":"RB Merrifield","year":"1963","unstructured":"Merrifield, R. B. Solid phase peptide synthesis. I. The synthesis of a tetrapeptide. J. Am. Chem. Soc. 85, 2149\u20132154 (1963).","journal-title":"J. Am. Chem. Soc."},{"key":"135_CR2","unstructured":"Reichert, J. Development trends for peptide therapeutics (Peptide Therapeutics Foundation, 2010)."},{"key":"135_CR3","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1016\/j.drudis.2014.10.003","volume":"20","author":"K Fosgerau","year":"2014","unstructured":"Fosgerau, K. & Hoffmann, T. Peptide therapeutics: current status and future directions. Drug Discov. Today 20, 122\u2013128 (2014).","journal-title":"Drug Discov. Today"},{"key":"135_CR4","doi-asserted-by":"publisher","first-page":"2700","DOI":"10.1016\/j.bmc.2017.06.052","volume":"26","author":"JL Lau","year":"2018","unstructured":"Lau, J. L. & Dunn, M. K. Therapeutic peptides: historical perspectives, current development trends, and future directions. Bioorg. Med. Chem. 26, 2700\u20132707 (2018).","journal-title":"Bioorg. Med. Chem."},{"key":"135_CR5","doi-asserted-by":"publisher","first-page":"16","DOI":"10.7326\/0003-4819-148-1-200801010-00189","volume":"148","author":"DB Matchar","year":"2008","unstructured":"Matchar, D. B. et al. Systematic review: comparative effectiveness of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers for treating essential hypertension. Ann. Intern. Med. 148, 16\u201329 (2008).","journal-title":"Ann. Intern. Med."},{"key":"135_CR6","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1111\/j.1751-7176.2011.00508.x","volume":"13","author":"JL Izzo Jr.","year":"2011","unstructured":"Izzo, J. L. Jr. & Weir, M. R. Angiotensin-converting enzyme inhibitors. J. Clin. Hypertens. 13, 667\u2013675 (2011).","journal-title":"J. Clin. Hypertens."},{"key":"135_CR7","doi-asserted-by":"publisher","first-page":"1731","DOI":"10.1016\/j.drudis.2014.06.026","volume":"19","author":"K Regulska","year":"2014","unstructured":"Regulska, K., Stanisz, B., Regulski, M. & Murias, M. How to design a potent, specific, and stable angiotensin-converting enzyme inhibitor. Drug Discov. Today 19, 1731\u20131743 (2014).","journal-title":"Drug Discov. Today"},{"key":"135_CR8","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1038\/nrd1227","volume":"2","author":"KR Acharya","year":"2003","unstructured":"Acharya, K. R., Sturrock, E. D., Rirodan, J. F. & Ehlers, M. R. W. ACE revisited: a new target for structure-based drug design. Nat. Rev. Drug Discov. 2, 891\u2013902 (2003).","journal-title":"Nat. Rev. Drug Discov."},{"key":"135_CR9","doi-asserted-by":"publisher","first-page":"1764","DOI":"10.2174\/1381612820666141112160013","volume":"21","author":"M Regulski","year":"2015","unstructured":"Regulski, M. et al. Chemistry and pharmacology of angiotensin-converting enzyme inhibitors. Curr. Pharm. Des. 21, 1764\u20131775 (2015).","journal-title":"Curr. Pharm. Des."},{"key":"135_CR10","doi-asserted-by":"publisher","first-page":"2850","DOI":"10.1016\/j.bmc.2017.08.006","volume":"26","author":"A Luther","year":"2018","unstructured":"Luther, A., Bisang, C. & Obrecht, D. Advances in macrocyclic peptide-based antibiotics. Bioorg. Med. Chem. 26, 2850\u20132858 (2018).","journal-title":"Bioorg. Med. Chem."},{"key":"135_CR11","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1038\/nature17042","volume":"529","author":"ED Brown","year":"2016","unstructured":"Brown, E. D. & Wright, G. D. Antibacterial drug discovery in the resistance era. Nature 529, 336\u2013343 (2016).","journal-title":"Nature"},{"key":"135_CR12","unstructured":"Infoholic Research LLP. Global Human Insulin Market 2018\u20132024. Research and Markets, ID: 4470733 (2018)."},{"key":"135_CR13","doi-asserted-by":"publisher","first-page":"4399","DOI":"10.2174\/092986709789712907","volume":"16","author":"JJ Nestor","year":"2009","unstructured":"Nestor, J. J. The medicinal chemistry of peptides. Curr. Med. Chem. 16, 4399\u20134418 (2009).","journal-title":"Curr. Med. Chem."},{"key":"135_CR14","doi-asserted-by":"publisher","first-page":"963","DOI":"10.2174\/0929867024606731","volume":"9","author":"C Adessi","year":"2002","unstructured":"Adessi, C. & Soto, C. Converting a peptide into a drug: strategies to improve stability and bioavailability. Curr. Med. Chem. 9, 963\u2013978 (2002).","journal-title":"Curr. Med. Chem."},{"key":"135_CR15","doi-asserted-by":"publisher","first-page":"3185","DOI":"10.2174\/138161210793292555","volume":"16","author":"L Gentilucci","year":"2010","unstructured":"Gentilucci, L., De Marco, R. & Cerisoli, L. Chemical modifications designed to improve peptide stability: incorporation of non-natural amino acids, pseudo-peptide bonds, and cyclization. Curr. Pharm. Des. 16, 3185\u20133203 (2010).","journal-title":"Curr. Pharm. Des."},{"key":"135_CR16","unstructured":"Jost, K., Lebl, M. & Brtnik, F. CRC Handbook of Neurohypophyseal Hormone Analogs. Volumes I & II (eds Jost, K., Lebl, M. & Brtnik, F.). (CRC Press, 1987)."},{"key":"135_CR17","doi-asserted-by":"publisher","first-page":"1250","DOI":"10.1135\/cccc19671250","volume":"32","author":"M Zaoral","year":"1967","unstructured":"Zaoral, M., Kolc, J. & Sorm, F. Amino acids and peptides. LXXI. Synthesis of 1-deamino-8-D-gamma-aminobutyrine vasopressin, 1-deamino-8-D-lysine vasopressin, and 1-deamino-8-D-arginine vasopressin. Collect. Czech. Chem. Commun. 32, 1250\u20131257 (1967).","journal-title":"Collect. Czech. Chem. Commun."},{"key":"135_CR18","doi-asserted-by":"publisher","first-page":"1260","DOI":"10.1016\/S0140-6736(77)92467-9","volume":"1","author":"SB Dimson","year":"1977","unstructured":"Dimson, S. B. Desmopressin as a treatment for enuresis. Lancet 1, 1260 (1977).","journal-title":"Lancet"},{"key":"135_CR19","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1677\/joe.0.1110125","volume":"111","author":"P Melin","year":"1986","unstructured":"Melin, P., Trojnar, J., Johansson, B., Vilhardt, H. & Aakerlund, M. Synthetic antagonists of the myometrial response to vasopressin and oxytocin. J. Endocrinol. 111, 125\u2013131 (1986).","journal-title":"J. Endocrinol."},{"key":"135_CR20","doi-asserted-by":"publisher","first-page":"PC64","DOI":"10.1016\/S0021-9258(18)64530-2","volume":"235","author":"V Du Vigneaud","year":"1960","unstructured":"Du Vigneaud, V., Winestock, G., Murti, V. V., Hope, D. B. & Kimbrough, R. D. Jr. Synthesis of 1-beta-mercantopropionic acid oxytocin (desamino-oxytocin), a highly potent analogue of oxytocin. J. Biol. Chem. 235, PC64\u2013PC66 (1960).","journal-title":"J. Biol. Chem."},{"key":"135_CR21","doi-asserted-by":"publisher","first-page":"1563","DOI":"10.1016\/S0021-9258(19)83740-7","volume":"237","author":"DB Hope","year":"1962","unstructured":"Hope, D. B., Murti, V. V. S. & du Vigneaud, V. A highly potent analog of oxytocin, deaminooxytocin. J. Biol. Chem. 237, 1563\u20131566 (1962).","journal-title":"J. Biol. Chem."},{"key":"135_CR22","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1021\/jm00267a004","volume":"16","author":"M Manning","year":"1973","unstructured":"Manning, M., Balaspiri, L., Acosta, M. & Sawyer, W. H. Solid phase synthesis of [1-deamino,4-valine]-8-D-arginine-vasopressin (DVDAVP), a highly potent and specific antidiuretic agent possessing protracted effects. J. Med. Chem. 16, 975\u2013978 (1973).","journal-title":"J. Med. Chem."},{"key":"135_CR23","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1677\/joe.0.0480157","volume":"48","author":"J Kyncl","year":"1970","unstructured":"Kyncl, J. & Rudinger, J. Excretion of antidiuretic activity in the urine of cats and rats after administration of the synthetic hormonogen, N\u03b1-glycyl-glycyl-glycyl-[8-lysine]-vasopressin (triglycylvasopressin). J. Endocrinol. 48, 157\u2013165 (1970).","journal-title":"J. Endocrinol."},{"key":"135_CR24","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1021\/jm00178a003","volume":"23","author":"M Kruszynski","year":"1980","unstructured":"Kruszynski, M. et al. [1-(\u03b2-mercapto-\u03b2,\u03b2-cyclopentamethylenepropionic acid),2-(O-methyl)tyrosine]arginine-vasopressin and [1-(\u03b2-mercapto-\u03b2,\u03b2-cyclopentamethylenepropionic acid)]arginine-vasopressin, two highly potent antagonists of the vasopressor response to arginine-vasopressin. J. Med. Chem. 23, 364\u2013368 (1980).","journal-title":"J. Med. Chem."},{"key":"135_CR25","doi-asserted-by":"publisher","first-page":"1373","DOI":"10.1073\/pnas.74.4.1373","volume":"74","author":"JP Meraldi","year":"1977","unstructured":"Meraldi, J. P., Hruby, V. J. & Brewster, A. I. R. Relative conformational rigidity in oxytocin and [1-penicillamine]oxytocin: a proposal for the relation of conformational flexibility to peptide hormone agonism and antagonism. Proc. Natl Acad. Sci. USA 74, 1373\u20131377 (1977).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"135_CR26","doi-asserted-by":"publisher","first-page":"1331","DOI":"10.1021\/ja00958a053","volume":"88","author":"R Walter","year":"1966","unstructured":"Walter, R. & du Vigneaud, V. 1-Deamino-1,6-L-selenocystineoxytocin; a highly potent isolog of 1-deaminooxytocin. J. Am. Chem. Soc. 88, 1331\u20131332 (1966).","journal-title":"J. Am. Chem. Soc."},{"key":"135_CR27","doi-asserted-by":"publisher","first-page":"4192","DOI":"10.1021\/ja01096a036","volume":"87","author":"R Walter","year":"1965","unstructured":"Walter, R. & du Vigneaud, V. 6-Hemi-L-selenocystine-oxytocin and 1-deamino-6-hemi-L-selenocystine-oxytocin, highly potent isologs of oxytocin and 1-deamino-oxytocin. J. Am. Chem. Soc. 87, 4192\u20134193 (1965).","journal-title":"J. Am. Chem. Soc."},{"key":"135_CR28","first-page":"474","volume":"6","author":"T Yamanaka","year":"1970","unstructured":"Yamanaka, T. et al. Crystalline deamino-dicarba-oxytocin. Preparation and some pharmacological properties. Mol. Pharmacol. 6, 474\u2013480 (1970).","journal-title":"Mol. Pharmacol."},{"key":"135_CR29","first-page":"528","volume":"47","author":"G Sweeney","year":"1990","unstructured":"Sweeney, G. et al. Pharmacokinetics of carbetocin, a long-acting oxytocin analog, in nonpregnant women. Curr. Ther. Res. 47, 528\u2013540 (1990).","journal-title":"Curr. Ther. Res."},{"key":"135_CR30","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1111\/j.1365-2826.2012.02303.x","volume":"24","author":"M Manning","year":"2012","unstructured":"Manning, M. et al. Oxytocin and vasopressin agonists and antagonists as research tools and potential therapeutics. J. Neuroendocrinol. 24, 609\u2013628 (2012).","journal-title":"J. Neuroendocrinol."},{"key":"135_CR31","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1016\/S0079-6123(08)00437-8","volume":"170","author":"M Manning","year":"2008","unstructured":"Manning, M. et al. Peptide and non-peptide agonists and antagonists for the vasopressin and oxytocin V1a, V1b, V2 and OT receptors: research tools and potential therapeutic agents. Prog. Brain Res. 170, 473\u2013512 (2008).","journal-title":"Prog. Brain Res."},{"key":"135_CR32","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/0006-291X(73)91073-5","volume":"50","author":"N Ling","year":"1973","unstructured":"Ling, N., Burgus, R., Rivier, J., Vale, W. & Brazeau, P. Use of mass spectrometry in deducing the sequence of somatostatin, a hypothalamic polypeptide that inhibits the secretion of growth hormone. Biochem. Biophys. Res. Commun. 50, 127\u2013133 (1973).","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"135_CR33","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.yfrne.2013.07.005","volume":"34","author":"M Theodoropoulou","year":"2013","unstructured":"Theodoropoulou, M. & Stalla, G. K. Somatostatin receptors: from signaling to clinical practice. Front. Neuroendocrinol. 34, 228\u2013252 (2013).","journal-title":"Front. Neuroendocrinol."},{"key":"135_CR34","doi-asserted-by":"publisher","first-page":"2595","DOI":"10.1002\/anie.200705797","volume":"47","author":"E Biron","year":"2008","unstructured":"Biron, E. et al. Improving oral bioavailability of peptides by multiple N-methylation: somatostatin analogues. Angew. Chem. Int. Ed. 47, 2595\u20132599 (2008).","journal-title":"Angew. Chem. Int. Ed."},{"key":"135_CR35","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1034\/j.1399-3011.2001.00873.x","volume":"58","author":"A Janecka","year":"2001","unstructured":"Janecka, A., Zubrzycka, M. & Janecki, T. Somatostatin analogs. J. Pept. Res. 58, 91\u2013107 (2001).","journal-title":"J. Pept. Res."},{"key":"135_CR36","unstructured":"Vale, W., Brown, M., Rivier, C., Perrin, M. & Rivier, J. Development and applications of analogs of LRF and somatostatin. in Brain Peptides: A New Endocrinology, 71\u201388 (Elsevier\/North-Holland Biomedical Press, 1979)."},{"key":"135_CR37","doi-asserted-by":"publisher","first-page":"1733","DOI":"10.1093\/annonc\/mdl105","volume":"17","author":"C Susini","year":"2006","unstructured":"Susini, C. & Buscail, L. Rationale for the use of somatostatin analogs as antitumor agents. Ann. Oncol. 17, 1733\u20131742 (2006).","journal-title":"Ann. Oncol."},{"key":"135_CR38","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1021\/ar800188e","volume":"42","author":"M De Jong","year":"2009","unstructured":"De Jong, M., Breeman, W. A. P., Kwekkeboom, D. J., Valkema, R. & Krenning, E. P. Tumor imaging and therapy using radiolabeled somatostatin analogues. Acc. Chem. Res. 42, 873\u2013880 (2009).","journal-title":"Acc. Chem. Res."},{"key":"135_CR39","doi-asserted-by":"publisher","first-page":"1319","DOI":"10.1007\/s002590100574","volume":"28","author":"DJ Kwekkeboom","year":"2001","unstructured":"Kwekkeboom, D. J. et al. [177Lu-DOTA0Tyr3]octreotate: comparison with [111In-DTPA0]octreotide in patients. Eur. J. Nucl. Med. 28, 1319\u20131325 (2001).","journal-title":"Eur. J. Nucl. Med."},{"key":"135_CR40","doi-asserted-by":"publisher","first-page":"4617","DOI":"10.1158\/1078-0432.CCR-16-2743","volume":"23","author":"T Brabander","year":"2017","unstructured":"Brabander, T. et al. Long-term efficacy, survival, and safety of [177Lu-DOTA0,Tyr3]octreotate in patients with gastroenteropancreatic and bronchial neuroendocrine tumors. Clin. Cancer Res. 23, 4617\u20134624 (2017).","journal-title":"Clin. Cancer Res."},{"key":"135_CR41","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1056\/NEJMoa1607427","volume":"376","author":"J Strosberg","year":"2017","unstructured":"Strosberg, J. et al. Phase 3 trial of 177Lu-Dotatate for midgut neuroendocrine tumors. N. Engl. J. Med. 376, 125\u2013135 (2017).","journal-title":"N. Engl. J. Med."},{"key":"135_CR42","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1038\/nrendo.2013.120","volume":"9","author":"RP Millar","year":"2013","unstructured":"Millar, R. P. & Newton, C. L. Current and future applications of GnRH, kisspeptin and neurokinin B analogues. Nat. Rev. Endocrinol. 9, 451\u2013466 (2013).","journal-title":"Nat. Rev. Endocrinol."},{"key":"135_CR43","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1097\/GCO.0b013e328348a3ce","volume":"23","author":"O Tan","year":"2011","unstructured":"Tan, O. & Bukulmez, O. Biochemistry, molecular biology and cell biology of gonadotropin-releasing hormone antagonists. Curr. Opin. Obstet. Gynecol. 23, 238\u2013244 (2011).","journal-title":"Curr. Opin. Obstet. Gynecol."},{"key":"135_CR44","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1038\/nrd4363","volume":"13","author":"S Mitragotri","year":"2014","unstructured":"Mitragotri, S., Burke, P. A. & Langer, R. Overcoming the challenges in administering biopharmaceuticals: formulation and delivery strategies. Nat. Rev. Drug Discov. 13, 655\u2013672 (2014).","journal-title":"Nat. Rev. Drug Discov."},{"key":"135_CR45","doi-asserted-by":"publisher","first-page":"1279","DOI":"10.4155\/tde.15.71","volume":"6","author":"J Zhang","year":"2015","unstructured":"Zhang, J., Desale, S. S. & Bronich, T. K. Polymer-based vehicles for therapeutic peptide delivery. Ther. Deliv. 6, 1279\u20131296 (2015).","journal-title":"Ther. Deliv."},{"key":"135_CR46","first-page":"52","volume":"20","author":"Y Wang","year":"2017","unstructured":"Wang, Y., Qu, W. & Choi, S. H. FDA\u2019s regulatory science program for generic PLA\/PLGA-based drug products. Am. Pharm. Rev. 20, 52\u201355 (2017).","journal-title":"Am. Pharm. Rev."},{"key":"135_CR47","doi-asserted-by":"publisher","first-page":"1056","DOI":"10.1126\/science.412251","volume":"198","author":"K Itakura","year":"1977","unstructured":"Itakura, K. et al. Expression in Escherichia coli of a chemically synthesized gene for the hormone somatostatin. Science 198, 1056\u20131063 (1977).","journal-title":"Science"},{"key":"135_CR48","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1126\/science.6337396","volume":"219","author":"IS Johnson","year":"1983","unstructured":"Johnson, I. S. Human insulin from recombinant DNA technology. Science 219, 632\u2013637 (1983).","journal-title":"Science"},{"key":"135_CR49","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1038\/nrd.2015.36","volume":"15","author":"AN Zaykov","year":"2016","unstructured":"Zaykov, A. N., Mayer, J. P. & DiMarchi, R. D. Pursuit of a perfect insulin. Nat. Rev. Drug Discov. 15, 425\u2013439 (2016).","journal-title":"Nat. Rev. Drug Discov."},{"key":"135_CR50","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1073\/pnas.76.1.106","volume":"76","author":"DV Goeddel","year":"1979","unstructured":"Goeddel, D. V. et al. Expression in Escherichia coli of chemically synthesized genes for human insulin. Proc. Natl Acad. Sci. USA 76, 106\u2013110 (1979).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"135_CR51","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1056\/NEJMra040832","volume":"352","author":"IB Hirsch","year":"2005","unstructured":"Hirsch, I. B. Insulin analogues. N. Engl. J. Med. 352, 174\u2013183 (2005).","journal-title":"N. Engl. J. Med."},{"key":"135_CR52","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1515\/JPEM.2004.17.7.931","volume":"17","author":"AM Inzerillo","year":"2004","unstructured":"Inzerillo, A. M., Zaidi, M. & Huang, C. L. H. Calcitonin: physiological actions and clinical applications. J. Pediatr. Endocrinol. Metab. 17, 931\u2013940 (2004).","journal-title":"J. Pediatr. Endocrinol. Metab."},{"key":"135_CR53","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1038\/193381a0","volume":"193","author":"DH Copp","year":"1962","unstructured":"Copp, D. H. & Cheney, B. Calcitonin-a hormone from the parathyroid which lowers the calcium level of the blood. Nature 193, 381\u2013382 (1962).","journal-title":"Nature"},{"key":"135_CR54","doi-asserted-by":"publisher","first-page":"2038","DOI":"10.1126\/science.134.3495.2038.a","volume":"134","author":"DH Copp","year":"1961","unstructured":"Copp, D. H. & Cameron, E. C. Demonstration of a hypocalcemic factor (calcitonin) in commercial parathyroid extract. Science 134, 2038 (1961).","journal-title":"Science"},{"key":"135_CR55","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1016\/S0021-9258(18)85007-4","volume":"63","author":"JB Collip","year":"1925","unstructured":"Collip, J. B. The extraction of a parathyroid hormone which will prevent or control parathyroid tetany and which regulates the level of blood calcium. J. Biol. Chem. 63, 395\u2013438 (1925).","journal-title":"J. Biol. Chem."},{"key":"135_CR56","doi-asserted-by":"publisher","first-page":"1293","DOI":"10.1007\/s40265-015-0438-2","volume":"75","author":"ES Kim","year":"2015","unstructured":"Kim, E. S. & Keating, G. M. Recombinant human parathyroid hormone (1\u201384): a review in hypoparathyroidism. Drugs 75, 1293\u20131303 2015).","journal-title":"Drugs"},{"key":"135_CR57","doi-asserted-by":"publisher","first-page":"922","DOI":"10.1210\/js.2018-00118","volume":"2","author":"AV Haas","year":"2018","unstructured":"Haas, A. V. & LeBoff, M. S. Osteoanabolic agents for osteoporosis. J. Endocr. Soc. 2, 922\u2013932 (2018).","journal-title":"J. Endocr. Soc."},{"key":"135_CR58","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1016\/j.synbio.2018.09.003","volume":"3","author":"Y Huang","year":"2018","unstructured":"Huang, Y. & Liu, T. Therapeutic applications of genetic code expansion. Synth. Syst. Biotechnol. 3, 150\u2013158 (2018).","journal-title":"Synth. Syst. Biotechnol."},{"key":"135_CR59","doi-asserted-by":"publisher","first-page":"854","DOI":"10.1021\/acschembio.7b00974","volume":"13","author":"DD Young","year":"2018","unstructured":"Young, D. D. & Schultz, P. G. Playing with the molecules of life. ACS Chem. Biol. 13, 854\u2013870 (2018).","journal-title":"ACS Chem. Biol."},{"key":"135_CR60","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1016\/j.cbpa.2018.07.020","volume":"46","author":"P Arranz-Gibert","year":"2018","unstructured":"Arranz-Gibert, P., Vanderschuren, K. & Isaacs, F. J. Next-generation genetic code expansion. Curr. Opin. Chem. Biol. 46, 203\u2013211 (2018).","journal-title":"Curr. Opin. Chem. Biol."},{"key":"135_CR61","doi-asserted-by":"publisher","first-page":"6131","DOI":"10.1021\/ja710016v","volume":"130","author":"AO Subtelny","year":"2008","unstructured":"Subtelny, A. O., Hartman, M. C. T. & Szostak, J. W. Ribosomal synthesis of N-methyl peptides. J. Am. Chem. Soc. 130, 6131\u20136136 (2008).","journal-title":"J. Am. Chem. Soc."},{"key":"135_CR62","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1016\/j.chembiol.2007.12.008","volume":"15","author":"T Kawakami","year":"2008","unstructured":"Kawakami, T., Murakami, H. & Suga, H. Messenger RNA-programmed incorporation of multiple N-methyl-amino acids into linear and cyclic peptides. Chem. Biol. 15, 32\u201342 (2008).","journal-title":"Chem. Biol."},{"key":"135_CR63","doi-asserted-by":"publisher","first-page":"1390","DOI":"10.1261\/rna.1020708","volume":"14","author":"Y Goto","year":"2008","unstructured":"Goto, Y., Murakami, H. & Suga, H. Initiating translation with D-amino acids. RNA 14, 1390\u20131398 (2008).","journal-title":"RNA"},{"key":"135_CR64","doi-asserted-by":"publisher","first-page":"1830","DOI":"10.1021\/ja309570x","volume":"135","author":"T Fujino","year":"2013","unstructured":"Fujino, T., Goto, Y., Suga, H. & Murakami, H. Reevaluation of the D-amino acid compatibility with the elongation event in translation. J. Am. Chem. Soc. 135, 1830\u20131837 (2013).","journal-title":"J. Am. Chem. Soc."},{"key":"135_CR65","doi-asserted-by":"publisher","first-page":"5687","DOI":"10.1093\/nar\/gkv566","volume":"43","author":"J Achenbach","year":"2015","unstructured":"Achenbach, J. et al. Outwitting EF-Tu and the ribosome: translation with D-amino acids. Nucleic Acids Res. 43, 5687\u20135698 (2015).","journal-title":"Nucleic Acids Res."},{"key":"135_CR66","doi-asserted-by":"publisher","first-page":"1962","DOI":"10.1021\/jacs.5b12482","volume":"138","author":"T Fujino","year":"2016","unstructured":"Fujino, T., Goto, Y., Suga, H. & Murakami, H. Ribosomal synthesis of peptides with multiple \u03b2-amino acids. J. Am. Chem. Soc. 138, 1962\u20131969 (2016).","journal-title":"J. Am. Chem. Soc."},{"key":"135_CR67","doi-asserted-by":"publisher","first-page":"12159","DOI":"10.1021\/jacs.8b07247","volume":"140","author":"T Katoh","year":"2018","unstructured":"Katoh, T. & Suga, H. Ribosomal incorporation of consecutive \u03b2-amino acids. J. Am. Chem. Soc. 140, 12159\u201312167 (2018).","journal-title":"J. Am. Chem. Soc."},{"key":"135_CR68","doi-asserted-by":"publisher","first-page":"20004","DOI":"10.1021\/jacs.9b11097","volume":"141","author":"R Maini","year":"2019","unstructured":"Maini, R. et al. Ribosomal formation of thioamide bonds in polypeptide synthesis. J. Am. Chem. Soc. 141, 20004\u201320008 (2019).","journal-title":"J. Am. Chem. Soc."},{"key":"135_CR69","doi-asserted-by":"publisher","first-page":"16861","DOI":"10.1021\/ja806998v","volume":"130","author":"T Kawakami","year":"2008","unstructured":"Kawakami, T., Murakami, H. & Suga, H. Ribosomal synthesis of polypeptoids and peptoid-peptide hybrids. J. Am. Chem. Soc. 130, 16861\u201316863 (2008).","journal-title":"J. Am. Chem. Soc."},{"key":"135_CR70","doi-asserted-by":"publisher","first-page":"10360","DOI":"10.1021\/acs.chemrev.8b00430","volume":"119","author":"Y Huang","year":"2018","unstructured":"Huang, Y., Wiedmann, M. M. & Suga, H. RNA display methods for the discovery of bioactive macrocycles. Chem. Rev. 119, 10360\u201310391 (2018).","journal-title":"Chem. Rev."},{"key":"135_CR71","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.ddtec.2017.10.005","volume":"26","author":"RD Taylor","year":"2017","unstructured":"Taylor, R. D., Rey-Carrizo, M., Passioura, T. & Suga, H. Identification of nonstandard macrocyclic peptide ligands through display screening. Drug Discov. Today Technol. 26, 17\u201323 (2017).","journal-title":"Drug Discov. Today Technol."},{"key":"135_CR72","doi-asserted-by":"publisher","first-page":"1931","DOI":"10.1039\/C6CC06951G","volume":"53","author":"T Passioura","year":"2017","unstructured":"Passioura, T. & Suga, H. A RaPID way to discover nonstandard macrocyclic peptide modulators of drug targets. Chem. Commun. 53, 1931\u20131940 (2017).","journal-title":"Chem. Commun."},{"key":"135_CR73","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1007\/BF01973261","volume":"6","author":"JF Borel","year":"1976","unstructured":"Borel, J. F., Feurer, C., Gubler, H. U. & Staehelin, H. Biological effects of cyclosporin A: a new antilymphocytic agent. Agents Actions 6, 468\u2013475 (1976).","journal-title":"Agents Actions"},{"key":"135_CR74","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1007\/BF01922409","volume":"52","author":"HF Saehelin","year":"1996","unstructured":"Saehelin, H. F. The history of cyclosporin A (Sandimmune) revisited: another point of view. Experientia 52, 5\u201313 (1996).","journal-title":"Experientia"},{"key":"135_CR75","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/S0169-409X(00)00129-0","volume":"46","author":"CA Lipinski","year":"2001","unstructured":"Lipinski, C. A., Lombardo, F., Dominy, B. W. & Feeney, P. J. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv. Drug Deliv. Rev. 46, 3\u201326 (2001).","journal-title":"Adv. Drug Deliv. Rev."},{"key":"135_CR76","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1126\/science.2374926","volume":"249","author":"TJ Rydel","year":"1990","unstructured":"Rydel, T. J. et al. The structure of a complex of recombinant hirudin and human \u03b1-thrombin. Science 249, 277\u2013280 (1990).","journal-title":"Science"},{"key":"135_CR77","doi-asserted-by":"publisher","first-page":"1349","DOI":"10.1517\/14656566.6.8.1349","volume":"6","author":"TE Warkentin","year":"2005","unstructured":"Warkentin, T. E. & Koster, A. Bivalirudin: a review. Expert Opin. Pharmacother. 6, 1349\u20131371 (2005).","journal-title":"Expert Opin. Pharmacother."},{"key":"135_CR78","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1002\/psc.2836","volume":"22","author":"R Behrendt","year":"2016","unstructured":"Behrendt, R., White, P. & Offer, J. Advances in Fmoc solid-phase peptide synthesis. J. Pept. Sci. 22, 4\u201327 (2016).","journal-title":"J. Pept. Sci."},{"key":"135_CR79","doi-asserted-by":"publisher","first-page":"3247","DOI":"10.1038\/nprot.2007.454","volume":"2","author":"I Coin","year":"2007","unstructured":"Coin, I., Beyermann, M. & Bienert, M. Solid-phase peptide synthesis: from standard procedures to the synthesis of difficult sequences. Nat. Protoc. 2, 3247\u20133256 (2007).","journal-title":"Nat. Protoc."},{"key":"135_CR80","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1039\/C5CS00680E","volume":"45","author":"M Paradis-Bas","year":"2016","unstructured":"Paradis-Bas, M., Tulla-Puche, J. & Albericio, F. The road to the synthesis of \u201cdifficult peptides\u201d. Chem. Soc. Rev. 45, 631\u2013654 (2016).","journal-title":"Chem. Soc. Rev."},{"key":"135_CR81","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1111\/j.1399-3011.1992.tb00291.x","volume":"40","author":"M Schn\u00f6lzer","year":"1992","unstructured":"Schn\u00f6lzer, M., Alewood, P. F., Jones, A., Alewood, D. & Kent, S. B. H. In situ neutralization in Boc-chemistry solid phase peptide synthesis. Rapid, high yield assembly of difficult sequences. Int. J. Pept. Protein Res. 40, 180\u2013193 (1992).","journal-title":"Int. J. Pept. Protein Res."},{"key":"135_CR82","doi-asserted-by":"publisher","first-page":"776","DOI":"10.1126\/science.7973629","volume":"266","author":"PE Dawson","year":"1994","unstructured":"Dawson, P. E., Muir, T. W., Clark-Lewis, I. & Kent, S. B. Synthesis of proteins by native chemical ligation. Science 266, 776\u2013779 (1994).","journal-title":"Science"},{"key":"135_CR83","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1073\/pnas.96.4.1181","volume":"96","author":"LP Miranda","year":"1999","unstructured":"Miranda, L. P. & Alewood, P. F. Accelerated chemical synthesis of peptides and small proteins. Proc. Natl Acad. Sci. USA 96, 1181\u20131186 (1999).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"135_CR84","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1039\/B700141J","volume":"38","author":"SBH Kent","year":"2009","unstructured":"Kent, S. B. H. Total chemical synthesis of proteins. Chem. Soc. Rev. 38, 338\u2013351 (2009).","journal-title":"Chem. Soc. Rev."},{"key":"135_CR85","doi-asserted-by":"publisher","first-page":"4926","DOI":"10.1016\/j.bmc.2017.06.020","volume":"25","author":"S Kent","year":"2017","unstructured":"Kent, S. Chemical protein synthesis: inventing synthetic methods to decipher how proteins work. Bioorg. Med. Chem. 25, 4926\u20134937 (2017).","journal-title":"Bioorg. Med. Chem."},{"key":"135_CR86","doi-asserted-by":"publisher","first-page":"1469","DOI":"10.1517\/14712598.2011.621940","volume":"11","author":"GF King","year":"2011","unstructured":"King, G. F. Venoms as a platform for human drugs: translating toxins into therapeutics. Expert Opin. Biol. Ther. 11, 1469\u20131484 (2011).","journal-title":"Expert Opin. Biol. Ther."},{"key":"135_CR87","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1080\/14789450.2017.1377613","volume":"14","author":"SD Robinson","year":"2017","unstructured":"Robinson, S. D., Undheim, E. A. B., Ueberheide, B. & King, G. F. Venom peptides as therapeutics: advances, challenges and the future of venom-peptide discovery. Expert Rev. Proteom. 14, 931\u2013939 (2017).","journal-title":"Expert Rev. Proteom."},{"key":"135_CR88","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1126\/science.aau7761","volume":"361","author":"M Holford","year":"2018","unstructured":"Holford, M., Daly, M., King, G. F. & Norton, R. S. Venoms to the rescue: insights into the evolutionary biology of venoms are leading to therapeutic advances. Science 361, 842\u2013844 (2018).","journal-title":"Science"},{"key":"135_CR89","doi-asserted-by":"publisher","first-page":"11510","DOI":"10.1021\/acs.chemrev.9b00207","volume":"119","author":"A-H Jin","year":"2019","unstructured":"Jin, A.-H. et al. Conotoxins: chemistry and biology. Chem. Rev. 119, 11510\u201311549 (2019).","journal-title":"Chem. Rev."},{"key":"135_CR90","doi-asserted-by":"publisher","first-page":"5815","DOI":"10.1021\/cr400401e","volume":"114","author":"KB Akondi","year":"2014","unstructured":"Akondi, K. B. et al. Discovery, synthesis, and structure-activity relationships of conotoxins. Chem. Rev. 114, 5815\u20135847 (2014).","journal-title":"Chem. Rev."},{"key":"135_CR91","doi-asserted-by":"publisher","first-page":"1696","DOI":"10.1016\/S0140-6736(06)69705-5","volume":"368","author":"DJ Drucker","year":"2006","unstructured":"Drucker, D. J. & Nauck, M. A. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet 368, 1696\u20131705 (2006).","journal-title":"Lancet"},{"key":"135_CR92","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/0167-0115(94)90136-8","volume":"51","author":"D Elahi","year":"1994","unstructured":"Elahi, D. et al. The insulinotropic actions of glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (7\u201337) in normal and diabetic subjects. Regul. Pept. 51, 63\u201375 (1994).","journal-title":"Regul. Pept."},{"key":"135_CR93","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.regpep.2003.10.028","volume":"117","author":"LL Nielsen","year":"2004","unstructured":"Nielsen, L. L., Young, A. A. & Parkes, D. G. Pharmacology of exenatide (synthetic exendin-4): a potential therapeutic for improved glycemic control of type 2 diabetes. Regul. Pept. 117, 77\u201388 (2004).","journal-title":"Regul. Pept."},{"key":"135_CR94","doi-asserted-by":"publisher","first-page":"7402","DOI":"10.1016\/S0021-9258(18)42531-8","volume":"267","author":"J Eng","year":"1992","unstructured":"Eng, J., Kleinman, W. A., Singh, L., Singh, G. & Raufman, J. P. Isolation and characterization of exendin-4, an exendin-3 analogue, from Heloderma suspectum venom. Further evidence for an exendin receptor on dispersed acini from guinea pig pancreas. J. Biol. Chem. 267, 7402\u20137405 (1992).","journal-title":"J. Biol. Chem."},{"key":"135_CR95","doi-asserted-by":"publisher","first-page":"PR1","DOI":"10.1021\/cr900344w","volume":"110","author":"G Ruiz-Gomez","year":"2010","unstructured":"Ruiz-Gomez, G., Tyndall, J. D., Pfeiffer, B., Abbenante, G. & Fairlie, D. P. Update 1 of: over one hundred peptide-activated G protein-coupled receptors recognize ligands with turn structure. Chem. Rev. 110, PR1\u2013PR41 (2010).","journal-title":"Chem. Rev."},{"key":"135_CR96","doi-asserted-by":"publisher","first-page":"1145","DOI":"10.1089\/dia.2011.0050","volume":"13","author":"MB DeYoung","year":"2011","unstructured":"DeYoung, M. B., MacConell, L., Sarin, V., Trautmann, M. & Herbert, P. Encapsulation of exenatide in poly-(D,L-lactide-Co-glycolide) microspheres produced an investigational long-acting once-weekly formulation for type 2 diabetes. Diabetes Technol. Ther. 13, 1145\u20131154 (2011).","journal-title":"Diabetes Technol. Ther."},{"key":"135_CR97","doi-asserted-by":"publisher","first-page":"3029","DOI":"10.2174\/0929867043363884","volume":"11","author":"GP Miljanich","year":"2004","unstructured":"Miljanich, G. P. Ziconotide: neuronal calcium channel blocker for treating severe chronic pain. Curr. Med. Chem. 11, 3029\u20133040 (2004).","journal-title":"Curr. Med. Chem."},{"key":"135_CR98","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1007\/s00726-010-0516-4","volume":"40","author":"I Vetter","year":"2011","unstructured":"Vetter, I. et al. Venomics: a new paradigm for natural products-based drug discovery. Amino Acids 40, 15\u201328 (2011).","journal-title":"Amino Acids"},{"key":"135_CR99","doi-asserted-by":"crossref","unstructured":"Dutertre, S. et al. in Venoms to Drugs: Venom as a Source for the Development of Human Therapeutics (ed. King, G. F.) 80\u201396 (Royal Society of Chemistry, 2015).","DOI":"10.1039\/9781849737876-00080"},{"key":"135_CR100","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0063865","volume":"8","author":"JK Klint","year":"2013","unstructured":"Klint, J. K. et al. Production of recombinant disulfide-rich venom peptides for structural and functional analysis via expression in the periplasm of E. coli. PLoS ONE 8, e63865 (2013).","journal-title":"PLoS ONE"},{"key":"135_CR101","doi-asserted-by":"publisher","first-page":"3514","DOI":"10.1021\/ja910602h","volume":"132","author":"M Muttenthaler","year":"2010","unstructured":"Muttenthaler, M. et al. Solving the \u03b1-conotoxin folding problem: efficient selenium-directed on-resin generation of more potent and stable nicotinic acetylcholine receptor antagonists. J. Am. Chem. Soc. 132, 3514\u20133522 (2010).","journal-title":"J. Am. Chem. Soc."},{"key":"135_CR102","doi-asserted-by":"publisher","first-page":"1223","DOI":"10.1002\/psc.1075","volume":"14","author":"M Muttenthaler","year":"2008","unstructured":"Muttenthaler, M. & Alewood, P. F. Selenopeptide chemistry. J. Pept. Sci. 14, 1223\u20131239 (2008).","journal-title":"J. Pept. Sci."},{"key":"135_CR103","doi-asserted-by":"crossref","unstructured":"Vetter, I., Hodgson, W. C., Adams, D. J. & McIntyre, P. in Venoms to drugs: venom as a source for the development of human therapeutics (ed. King, G. F.) 97\u2013128 (Royal Society of Chemistry, 2015).","DOI":"10.1039\/9781849737876-00097"},{"key":"135_CR104","doi-asserted-by":"publisher","first-page":"988","DOI":"10.1039\/C6NP00025H","volume":"33","author":"N Ziemert","year":"2016","unstructured":"Ziemert, N., Alanjary, M. & Weber, T. The evolution of genome mining in microbes - a review. Nat. Prod. Rep. 33, 988\u20131005 (2016).","journal-title":"Nat. Prod. Rep."},{"key":"135_CR105","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1016\/j.tcb.2017.04.006","volume":"27","author":"CA Makarewich","year":"2017","unstructured":"Makarewich, C. A. & Olson, E. N. Mining for micropeptides. Trends Cell Biol. 27, 685\u2013696 (2017).","journal-title":"Trends Cell Biol."},{"key":"135_CR106","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.cbpa.2017.02.005","volume":"38","author":"KJ Hetrick","year":"2017","unstructured":"Hetrick, K. J. & van der Donk, W. A. Ribosomally synthesized and post-translationally modified peptide natural product discovery in the genomic era. Curr. Opin. Chem. Biol. 38, 36\u201344 (2017).","journal-title":"Curr. Opin. Chem. Biol."},{"key":"135_CR107","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1038\/nchembio.2319","volume":"13","author":"JI Tietz","year":"2017","unstructured":"Tietz, J. I. et al. A new genome-mining tool redefines the lasso peptide biosynthetic landscape. Nat. Chem. Biol. 13, 470\u2013478 (2017).","journal-title":"Nat. Chem. Biol."},{"key":"135_CR108","doi-asserted-by":"publisher","first-page":"114129","DOI":"10.1016\/j.bcp.2020.114129","volume":"181","author":"HC Mendel","year":"2020","unstructured":"Mendel, H. C., Kaas, Q. & Muttenthaler, M. Neuropeptide signalling systems - an underexplored target for venom drug discovery. Biochem. Pharmacol. 181, 114129 (2020).","journal-title":"Biochem. Pharmacol."},{"key":"135_CR109","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0032559","volume":"7","author":"CW Gruber","year":"2012","unstructured":"Gruber, C. W. & Muttenthaler, M. Discovery of defense- and neuropeptides in social ants by genome-mining. PLoS ONE 7, e32559 (2012).","journal-title":"PLoS ONE"},{"key":"135_CR110","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1038\/nature14098","volume":"517","author":"LL Ling","year":"2015","unstructured":"Ling, L. L. et al. A new antibiotic kills pathogens without detectable resistance. Nature 517, 455\u2013459 (2015).","journal-title":"Nature"},{"key":"135_CR111","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1111\/nyas.14282","volume":"1459","author":"JA Karas","year":"2020","unstructured":"Karas, J. A. et al. Synthesis and structure-activity relationships of teixobactin. Ann. N. Y. Acad. Sci. 1459, 86\u2013105 (2020).","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"135_CR112","doi-asserted-by":"publisher","first-page":"12171","DOI":"10.1021\/acs.jmedchem.0c00173","volume":"63","author":"VB Gunjal","year":"2020","unstructured":"Gunjal, V. B., Thakare, R., Chopra, S. & Reddy, D. S. Teixobactin: a paving stone toward a new class of antibiotics? J. Med. Chem. 63, 12171\u201312195 (2020).","journal-title":"J. Med. Chem."},{"key":"135_CR113","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1038\/s41573-019-0058-8","volume":"19","author":"N Mookherjee","year":"2020","unstructured":"Mookherjee, N., Anderson, M. A., Haagsman, H. P. & Davidson, D. J. Antimicrobial host defence peptides: functions and clinical potential. Nat. Rev. Drug Discov. 19, 311\u2013332 (2020).","journal-title":"Nat. Rev. Drug Discov."},{"key":"135_CR114","first-page":"F185","volume":"233","author":"V Johnson","year":"1977","unstructured":"Johnson, V. & Maack, T. Renal extraction, filtration, absorption, and catabolism of growth hormone. Am. J. Physiol. 233, F185\u2013F196 (1977).","journal-title":"Am. J. Physiol."},{"key":"135_CR115","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1038\/ki.1979.128","volume":"16","author":"T Maack","year":"1979","unstructured":"Maack, T., Johnson, V., Kau, S. T., Figueiredo, J. & Sigulem, D. Renal filtration, transport, and metabolism of low-molecular-weight proteins: a review. Kidney Int. 16, 251\u2013270 (1979).","journal-title":"Kidney Int."},{"key":"135_CR116","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1159\/000181425","volume":"22","author":"AI Katz","year":"1978","unstructured":"Katz, A. I. & Emmanouel, D. S. Metabolism of polypeptide hormones by the normal kidney and in uremia. Nephron 22, 61\u201372 (1978).","journal-title":"Nephron"},{"key":"135_CR117","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1039\/C0MD00111B","volume":"1","author":"L Pollaro","year":"2010","unstructured":"Pollaro, L. & Heinis, C. Strategies to prolong the plasma residence time of peptide drugs. Med. Chem. Commun. 1, 319\u2013324 (2010).","journal-title":"Med. Chem. Commun."},{"key":"135_CR118","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/j.jconrel.2014.06.046","volume":"192","author":"A Kolate","year":"2014","unstructured":"Kolate, A. et al. PEG - a versatile conjugating ligand for drugs and drug delivery systems. J. Control. Release 192, 67\u201381 (2014).","journal-title":"J. Control. Release"},{"key":"135_CR119","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1042\/bj3120725","volume":"312","author":"P Kurtzhals","year":"1995","unstructured":"Kurtzhals, P. et al. Albumin binding of insulins acylated with fatty acids: characterization of the ligand-protein interaction and correlation between binding affinity and timing of the insulin effect in vivo. Biochem. J. 312, 725\u2013731 (1995).","journal-title":"Biochem. J."},{"key":"135_CR120","doi-asserted-by":"publisher","first-page":"1398","DOI":"10.2337\/diacare.25.8.1398","volume":"25","author":"B Elbrond","year":"2002","unstructured":"Elbrond, B. et al. Pharmacokinetics, pharmacodynamics, safety, and tolerability of a single-dose of NN2211, a long-acting glucagon-like peptide 1 derivative, in healthy male subjects. Diabetes Care 25, 1398\u20131404 (2002).","journal-title":"Diabetes Care"},{"key":"135_CR121","doi-asserted-by":"publisher","first-page":"2359","DOI":"10.1056\/NEJMoa072375","volume":"357","author":"J Falutz","year":"2007","unstructured":"Falutz, J. et al. Metabolic effects of a growth hormone-releasing factor in patients with HIV. N. Engl. J. Med. 357, 2359\u20132370 (2007).","journal-title":"N. Engl. J. Med."},{"key":"135_CR122","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1111\/j.1742-7843.2007.00008.x","volume":"100","author":"ES Ferdinandi","year":"2007","unstructured":"Ferdinandi, E. S. et al. Non-clinical pharmacology and safety evaluation of TH9507, a human growth hormone-releasing factor analogue. Basic Clin. Pharmacol. Toxicol. 100, 49\u201358 (2007).","journal-title":"Basic Clin. Pharmacol. Toxicol."},{"key":"135_CR123","doi-asserted-by":"publisher","first-page":"2492","DOI":"10.2337\/diabetes.53.9.2492","volume":"53","author":"LL Baggio","year":"2004","unstructured":"Baggio, L. L., Huang, Q., Brown, T. J. & Drucker, D. J. A recombinant human glucagon-like peptide (GLP)-1-albumin protein (Albugon) mimics peptidergic activation of GLP-1 receptor-dependent pathways coupled with satiety, gastrointestinal motility, and glucose homeostasis. Diabetes 53, 2492\u20132500 (2004).","journal-title":"Diabetes"},{"key":"135_CR124","doi-asserted-by":"publisher","first-page":"4810","DOI":"10.1210\/jc.2008-1518","volume":"93","author":"JE Matthews","year":"2008","unstructured":"Matthews, J. E. et al. Pharmacodynamics, pharmacokinetics, safety, and tolerability of albiglutide, a long-acting glucagon-like peptide-1 mimetic, in patients with type 2 diabetes. J. Clin. Endocrinol. Metab. 93, 4810\u20134817 (2008).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"135_CR125","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1002\/dmrr.1080","volume":"26","author":"W Glaesner","year":"2010","unstructured":"Glaesner, W. et al. Engineering and characterization of the long-acting glucagon-like peptide-1 analogue LY2189265, an Fc fusion protein. Diabetes Metab. Res. Rev. 26, 287\u2013296 (2010).","journal-title":"Diabetes Metab. Res. Rev."},{"key":"135_CR126","doi-asserted-by":"publisher","first-page":"1257","DOI":"10.1080\/17425247.2016.1182485","volume":"13","author":"AA D\u2019Souza","year":"2016","unstructured":"D\u2019Souza, A. A. & Shegokar, R. Polyethylene glycol (PEG): a versatile polymer for pharmaceutical applications. Expert Opin. Drug Deliv. 13, 1257\u20131275 (2016).","journal-title":"Expert Opin. Drug Deliv."},{"key":"135_CR127","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1080\/14728214.2019.1604684","volume":"24","author":"EJ Park","year":"2019","unstructured":"Park, E. J., Choi, J., Lee, K. C. & Na, D. H. Emerging PEGylated non-biologic drugs. Expert Opin. Emerg. Drugs 24, 107\u2013119 (2019).","journal-title":"Expert Opin. Emerg. Drugs"},{"key":"135_CR128","doi-asserted-by":"publisher","first-page":"884","DOI":"10.4049\/jimmunol.157.2.884","volume":"157","author":"A Sahu","year":"1996","unstructured":"Sahu, A., Kay, B. K. & Lambris, J. D. Inhibition of human complement by a C3-binding peptide isolated from a phage-displayed random peptide library. J. Immunol. 157, 884\u2013891 (1996).","journal-title":"J. Immunol."},{"key":"135_CR129","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1016\/j.ophtha.2019.07.011","volume":"127","author":"DS Liao","year":"2020","unstructured":"Liao, D. S. et al. Complement C3 inhibitor pegcetacoplan for geographic atrophy secondary to age-related macular degeneration: a randomized phase 2 trial. Ophthalmology 127, 186\u2013195 (2020).","journal-title":"Ophthalmology"},{"key":"135_CR130","doi-asserted-by":"publisher","first-page":"7064","DOI":"10.1016\/j.bmc.2013.09.016","volume":"21","author":"E Bianchi","year":"2013","unstructured":"Bianchi, E. et al. A PEGylated analog of the gut hormone oxyntomodulin with long-lasting antihyperglycemic, insulinotropic and anorexigenic activity. Bioorg. Med. Chem. 21, 7064\u20137073 (2013).","journal-title":"Bioorg. Med. Chem."},{"key":"135_CR131","doi-asserted-by":"publisher","first-page":"1315","DOI":"10.1126\/science.4001944","volume":"228","author":"GP Smith","year":"1985","unstructured":"Smith, G. P. Filamentous fusion phage: novel expression vectors that display cloned antigens on the virion surface. Science 228, 1315\u20131317 (1985).","journal-title":"Science"},{"key":"135_CR132","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1038\/nrd.2017.146","volume":"16","author":"AM Davis","year":"2017","unstructured":"Davis, A. M., Plowright, A. T. & Valeur, E. Directing evolution: the next revolution in drug discovery? Nat. Rev. Drug Discov. 16, 681\u2013698 (2017).","journal-title":"Nat. Rev. Drug Discov."},{"key":"135_CR133","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1517\/14656566.2013.780695","volume":"14","author":"H Schmid","year":"2013","unstructured":"Schmid, H. Peginesatide for the treatment of renal disease-induced anemia. Expert Opin. Pharmacother. 14, 937\u2013948 (2013).","journal-title":"Expert Opin. Pharmacother."},{"key":"135_CR134","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1056\/NEJMoa1203166","volume":"368","author":"IC MacDougall","year":"2013","unstructured":"MacDougall, I. C. et al. Peginesatide for anemia in patients with chronic kidney disease not receiving dialysis. N. Engl. J. Med. 368, 320\u2013332 (2013).","journal-title":"N. Engl. J. Med."},{"key":"135_CR135","doi-asserted-by":"publisher","first-page":"1421","DOI":"10.1080\/14740338.2016.1218467","volume":"15","author":"T Hermanson","year":"2016","unstructured":"Hermanson, T., Bennett, C. L. & MacDougall, I. C. Peginesatide for the treatment of anemia due to chronic kidney disease \u2013 an unfulfilled promise. Expert Opin. Drug Saf. 15, 1421\u20131426 (2016).","journal-title":"Expert Opin. Drug Saf."},{"key":"135_CR136","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1126\/science.273.5274.458","volume":"273","author":"NC Wrighton","year":"1996","unstructured":"Wrighton, N. C. et al. Small peptides as potent mimetics of the protein hormone erythropoietin. Science 273, 458\u2013463 (1996).","journal-title":"Science"},{"key":"135_CR137","doi-asserted-by":"publisher","first-page":"1261","DOI":"10.1038\/nbt1197-1261","volume":"15","author":"N Wrighton","year":"1997","unstructured":"Wrighton, N. et al. Increased potency of an erythropoietin peptide mimetic through covalent dimerization. Nat. Biotechnol. 15, 1261\u20131265 (1997).","journal-title":"Nat. Biotechnol."},{"key":"135_CR138","doi-asserted-by":"publisher","first-page":"1303","DOI":"10.1016\/j.exphem.2006.05.012","volume":"34","author":"Q Fan","year":"2006","unstructured":"Fan, Q. et al. Preclinical evaluation of Hematide, a novel erythropoiesis stimulating agent, for the treatment of anemia. Exp. Hematol. 34, 1303\u20131311 (2006).","journal-title":"Exp. Hematol."},{"key":"135_CR139","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1111\/j.1365-2141.2010.08140.x","volume":"150","author":"G Molineux","year":"2010","unstructured":"Molineux, G. & Newland, A. Development of romiplostim for the treatment of patients with chronic immune thrombocytopenia: from bench to bedside. Br. J. Haematol. 150, 9\u201320 (2010).","journal-title":"Br. J. Haematol."},{"key":"135_CR140","doi-asserted-by":"publisher","first-page":"1187","DOI":"10.1517\/14712598.8.8.1187","volume":"8","author":"A Lehmann","year":"2008","unstructured":"Lehmann, A. Ecallantide (DX-88), a plasma kallikrein inhibitor for the treatment of hereditary angioedema and the prevention of blood loss in on-pump cardiothoracic surgery. Expert Opin. Biol. Ther. 8, 1187\u20131199 (2008).","journal-title":"Expert Opin. Biol. Ther."},{"key":"135_CR141","doi-asserted-by":"publisher","first-page":"73","DOI":"10.4161\/mabs.27240","volume":"6","author":"AE Nixon","year":"2014","unstructured":"Nixon, A. E., Sexton, D. J. & Ladner, R. C. Drugs derived from phage display: from candidate identification to clinical practice. MAbs 6, 73\u201385 (2014).","journal-title":"MAbs"},{"key":"135_CR142","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1016\/j.cbpa.2017.02.016","volume":"38","author":"A Tavassoli","year":"2017","unstructured":"Tavassoli, A. SICLOPPS cyclic peptide libraries in drug discovery. Curr. Opin. Chem. Biol. 38, 30\u201335 (2017).","journal-title":"Curr. Opin. Chem. Biol."},{"key":"135_CR143","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/j.ymeth.2012.12.008","volume":"60","author":"I Rentero Rebollo","year":"2013","unstructured":"Rentero Rebollo, I. & Heinis, C. Phage selection of bicyclic peptides. Methods 60, 46\u201354 (2013).","journal-title":"Methods"},{"key":"135_CR144","doi-asserted-by":"publisher","first-page":"1866","DOI":"10.1021\/acs.accounts.7b00184","volume":"50","author":"K Deyle","year":"2017","unstructured":"Deyle, K., Kong, X.-D. & Heinis, C. Phage selection of cyclic peptides for application in research and drug development. Acc. Chem. Res. 50, 1866\u20131874 (2017).","journal-title":"Acc. Chem. Res."},{"key":"135_CR145","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1038\/s41551-020-0556-3","volume":"4","author":"X-D Kong","year":"2020","unstructured":"Kong, X.-D. et al. De novo development of proteolytically resistant therapeutic peptides for oral administration. Nat. Biomed. Eng. 4, 560\u2013571 (2020).","journal-title":"Nat. Biomed. Eng."},{"key":"135_CR146","doi-asserted-by":"publisher","first-page":"1861","DOI":"10.1021\/acschembio.5b00103","volume":"10","author":"V Baeriswyl","year":"2015","unstructured":"Baeriswyl, V. et al. A synthetic factor XIIa inhibitor blocks selectively intrinsic coagulation initiation. ACS Chem. Biol. 10, 1861\u20131870 (2015).","journal-title":"ACS Chem. Biol."},{"key":"135_CR147","doi-asserted-by":"publisher","first-page":"1151","DOI":"10.1021\/acs.jmedchem.6b01548","volume":"60","author":"SJ Middendorp","year":"2017","unstructured":"Middendorp, S. J. et al. Peptide macrocycle inhibitor of coagulation factor XII with subnanomolar affinity and high target selectivity. J. Med. Chem. 60, 1151\u20131158 (2017).","journal-title":"J. Med. Chem."},{"key":"135_CR148","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.cbpa.2014.09.019","volume":"22","author":"L Zhao","year":"2014","unstructured":"Zhao, L. & Lu, W. Mirror image proteins. Curr. Opin. Chem. Biol. 22, 56\u201361 (2014).","journal-title":"Curr. Opin. Chem. Biol."},{"key":"135_CR149","doi-asserted-by":"publisher","first-page":"15114","DOI":"10.1002\/anie.202002783","volume":"59","author":"X Zhou","year":"2020","unstructured":"Zhou, X. et al. A novel D-peptide identified by mirror-image phage display blocks TIGIT\/PVR for cancer immunotherapy. Angew. Chem. Int. Ed. 59, 15114\u201315118 (2020).","journal-title":"Angew. Chem. Int. Ed."},{"key":"135_CR150","doi-asserted-by":"publisher","first-page":"2079","DOI":"10.1002\/cbic.201900355","volume":"20","author":"C Diaz-Perlas","year":"2019","unstructured":"Diaz-Perlas, C. et al. Protein chemical synthesis combined with mirror-image phage display yields D-peptide EGF ligands that block the EGF-EGFR interaction. ChemBioChem 20, 2079\u20132084 (2019).","journal-title":"ChemBioChem"},{"key":"135_CR151","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0147470","volume":"11","author":"S Rudolph","year":"2016","unstructured":"Rudolph, S. et al. Competitive mirror image phage display derived peptide modulates amyloid beta aggregation and toxicity. PLoS ONE 11, e0147470 (2016).","journal-title":"PLoS ONE"},{"key":"135_CR152","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1007\/978-1-4939-9504-2_14","volume":"2001","author":"C Tsiamantas","year":"2019","unstructured":"Tsiamantas, C., Otero-Ramirez Manuel, E. & Suga, H. Discovery of functional macrocyclic peptides by means of the RaPID system. Methods Mol. Biol. 2001, 299\u2013315 (2019).","journal-title":"Methods Mol. Biol."},{"key":"135_CR153","doi-asserted-by":"publisher","first-page":"10469","DOI":"10.1021\/ja301017y","volume":"134","author":"YV Guillen Schlippe","year":"2012","unstructured":"Guillen Schlippe, Y. V., Hartman, M. C. T., Josephson, K. & Szostak, J. W. In vitro selection of highly modified cyclic peptides that act as tight binding inhibitors. J. Am. Chem. Soc. 134, 10469\u201310477 (2012).","journal-title":"J. Am. Chem. Soc."},{"key":"135_CR154","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1001\/jamaneurol.2019.5125","volume":"77","author":"JF Howard","year":"2020","unstructured":"Howard, J. F. et al. Clinical effects of the self-administered subcutaneous complement inhibitor zilucoplan in patients with moderate to severe generalized myasthenia gravis: results of a phase 2 randomized, double-blind, placebo-controlled, multicenter clinical trial. JAMA Neurol. 77, 582\u2013592 (2020).","journal-title":"JAMA Neurol."},{"key":"135_CR155","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1111\/cbdd.12055","volume":"81","author":"DJ Craik","year":"2013","unstructured":"Craik, D. J., Fairlie, D. P., Liras, S. & Price, D. The future of peptide-based drugs. Chem. Biol. Drug Des. 81, 136\u2013147 (2013).","journal-title":"Chem. Biol. Drug Des."},{"key":"135_CR156","doi-asserted-by":"publisher","first-page":"8094","DOI":"10.1021\/acs.chemrev.6b00838","volume":"117","author":"DS Nielsen","year":"2017","unstructured":"Nielsen, D. S. et al. Orally absorbed cyclic peptides. Chem. Rev. 117, 8094\u20138128 (2017).","journal-title":"Chem. Rev."},{"key":"135_CR157","doi-asserted-by":"publisher","first-page":"8585","DOI":"10.1021\/jm100989w","volume":"53","author":"M Muttenthaler","year":"2010","unstructured":"Muttenthaler, M. et al. Modulating oxytocin activity and plasma stability by disulfide bond engineering. J. Med. Chem. 53, 8585\u20138596 (2010).","journal-title":"J. Med. Chem."},{"key":"135_CR158","doi-asserted-by":"publisher","first-page":"2759","DOI":"10.1016\/j.bmc.2018.01.012","volume":"26","author":"M Erak","year":"2018","unstructured":"Erak, M., Bellmann-Sickert, K., Els-Heindl, S. & Beck-Sickinger, A. G. Peptide chemistry toolbox - Transforming natural peptides into peptide therapeutics. Bioorg. Med. Chem. 26, 2759\u20132765 (2018).","journal-title":"Bioorg. Med. Chem."},{"key":"135_CR159","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1016\/j.ejmech.2014.03.011","volume":"77","author":"SE Northfield","year":"2014","unstructured":"Northfield, S. E. et al. Disulfide-rich macrocyclic peptides as templates in drug design. Eur. J. Med. Chem. 77, 248\u2013257 (2014).","journal-title":"Eur. J. Med. Chem."},{"key":"135_CR160","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/j.cbpa.2017.03.017","volume":"38","author":"R Liu","year":"2017","unstructured":"Liu, R., Li, X. & Lam, K. S. Combinatorial chemistry in drug discovery. Curr. Opin. Chem. Biol. 38, 117\u2013126 (2017).","journal-title":"Curr. Opin. Chem. Biol."},{"key":"135_CR161","doi-asserted-by":"publisher","first-page":"1412","DOI":"10.1039\/C8NP00091C","volume":"36","author":"L Huo","year":"2019","unstructured":"Huo, L. et al. Heterologous expression of bacterial natural product biosynthetic pathways. Nat. Prod. Rep. 36, 1412\u20131436 (2019).","journal-title":"Nat. Prod. Rep."},{"key":"135_CR162","doi-asserted-by":"publisher","first-page":"6275","DOI":"10.1021\/jm4011675","volume":"57","author":"LD Walensky","year":"2014","unstructured":"Walensky, L. D. & Bird, G. H. Hydrocarbon-stapled peptides: principles, practice, and progress. J. Med. Chem. 57, 6275\u20136288 (2014).","journal-title":"J. Med. Chem."},{"key":"135_CR163","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/B978-0-12-396962-0.00001-X","volume":"503","author":"GL Verdine","year":"2012","unstructured":"Verdine, G. L. & Hilinski, G. J. Stapled peptides for intracellular drug targets. Methods Enzymol. 503, 3\u201333 (2012).","journal-title":"Methods Enzymol."},{"key":"135_CR164","doi-asserted-by":"publisher","first-page":"1362","DOI":"10.1021\/cb501020r","volume":"10","author":"PM Cromm","year":"2015","unstructured":"Cromm, P. M., Spiegel, J. & Grossmann, T. N. Hydrocarbon stapled peptides as modulators of biological function. ACS Chem. Biol. 10, 1362\u20131375 (2015).","journal-title":"ACS Chem. Biol."},{"key":"135_CR165","first-page":"10","volume":"1-10","author":"YS Chang","year":"2013","unstructured":"Chang, Y. S. et al. Stapled \u03b1-helical peptide drug development: A potent dual inhibitor of MDM2 and MDMX for p53-dependent cancer therapy. Proc. Natl Acad. Sci. USA 1-10, 10 (2013).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"135_CR166","doi-asserted-by":"publisher","first-page":"eaao3003","DOI":"10.1126\/scitranslmed.aao3003","volume":"10","author":"LA Carvajal","year":"2018","unstructured":"Carvajal, L. A. et al. Dual inhibition of MDMX and MDM2 as a therapeutic strategy in leukemia. Sci. Transl. Med. 10, eaao3003 (2018).","journal-title":"Sci. Transl. Med."},{"key":"135_CR167","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.cbpa.2017.01.017","volume":"38","author":"M Schmidt","year":"2017","unstructured":"Schmidt, M., Toplak, A., Quaedflieg, P. J. L. M. & Nuijens, T. Enzyme-mediated ligation technologies for peptides and proteins. Curr. Opin. Chem. Biol. 38, 1\u20137 (2017).","journal-title":"Curr. Opin. Chem. Biol."},{"key":"135_CR168","doi-asserted-by":"publisher","first-page":"4041","DOI":"10.1002\/adsc.201600774","volume":"358","author":"T Nuijens","year":"2016","unstructured":"Nuijens, T. et al. Engineering a diverse ligase toolbox for peptide segment condensation. Adv. Synth. Catal. 358, 4041\u20134048 (2016).","journal-title":"Adv. Synth. Catal."},{"key":"135_CR169","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1038\/nchembio.2318","volume":"13","author":"AJ Mijalis","year":"2017","unstructured":"Mijalis, A. J. et al. A fully automated flow-based approach for accelerated peptide synthesis. Nat. Chem. Biol. 13, 464\u2013466 (2017).","journal-title":"Nat. Chem. Biol."},{"key":"135_CR170","doi-asserted-by":"publisher","first-page":"122ra21","DOI":"10.1126\/scitranslmed.3003276","volume":"4","author":"R Farra","year":"2012","unstructured":"Farra, R. et al. First-in-human testing of a wirelessly controlled drug delivery microchip. Sci. Transl. Med. 4, 122ra21 (2012).","journal-title":"Sci. Transl. Med."},{"key":"135_CR171","doi-asserted-by":"publisher","first-page":"1637","DOI":"10.1517\/17425247.2015.1049531","volume":"12","author":"NC Hogan","year":"2015","unstructured":"Hogan, N. C., Taberner, A. J., Jones, L. A. & Hunter, I. W. Needle-free delivery of macromolecules through the skin using controllable jet injectors. Expert Opin. Drug Deliv. 12, 1637\u20131648 (2015).","journal-title":"Expert Opin. Drug Deliv."},{"key":"135_CR172","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1016\/j.jconrel.2014.12.006","volume":"199","author":"S Kumar","year":"2015","unstructured":"Kumar, S. et al. Peptides as skin penetration enhancers: mechanisms of action. J. Control. Release 199, 168\u2013178 (2015).","journal-title":"J. Control. Release"},{"key":"135_CR173","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.addr.2018.12.006","volume":"139","author":"Y Zhang","year":"2019","unstructured":"Zhang, Y. et al. Advances in transdermal insulin delivery. Adv. Drug Deliv. Rev. 139, 51\u201370 (2019).","journal-title":"Adv. Drug Deliv. Rev."},{"key":"135_CR174","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1089\/dia.2016.0156","volume":"18","author":"E Kochba","year":"2016","unstructured":"Kochba, E., Levin, Y., Raz, I. & Cahn, A. Improved insulin pharmacokinetics using a novel microneedle device for intradermal delivery in patients with type 2 diabetes. Diabetes Technol. Ther. 18, 525\u2013531 (2016).","journal-title":"Diabetes Technol. Ther."},{"key":"135_CR175","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1007\/s11095-010-0192-9","volume":"28","author":"PE Daddona","year":"2011","unstructured":"Daddona, P. E., Matriano, J. A., Mandema, J. & Maa, Y.-F. Parathyroid hormone (1-34)-coated microneedle patch system: clinical pharmacokinetics and pharmacodynamics for treatment of osteoporosis. Pharm. Res. 28, 159\u2013165 (2011).","journal-title":"Pharm. Res."},{"key":"135_CR176","doi-asserted-by":"publisher","first-page":"1679","DOI":"10.1007\/s40265-015-0472-0","volume":"75","author":"ES Kim","year":"2015","unstructured":"Kim, E. S. & Plosker, G. L. AFREZZA\u00ae (insulin human) inhalation powder: a review in diabetes mellitus. Drugs 75, 1679\u20131686 (2015).","journal-title":"Drugs"},{"key":"135_CR177","doi-asserted-by":"publisher","first-page":"555","DOI":"10.2337\/dc15-1606","volume":"39","author":"JL Sherr","year":"2016","unstructured":"Sherr, J. L. et al. Glucagon nasal powder: a promising alternative to intramuscular glucagon in youth with type 1 diabetes. Diabetes Care 39, 555\u2013562 (2016).","journal-title":"Diabetes Care"},{"key":"135_CR178","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1038\/s41573-019-0053-0","volume":"19","author":"DJ Drucker","year":"2020","unstructured":"Drucker, D. J. Advances in oral peptide therapeutics. Nat. Rev. Drug Discov. 19, 277\u2013289 (2020).","journal-title":"Nat. Rev. Drug Discov."},{"key":"135_CR179","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1016\/j.addr.2020.05.007","volume":"157","author":"DJ Brayden","year":"2020","unstructured":"Brayden, D. J., Hill, T. A., Fairlie, D. P., Maher, S. & Mrsny, R. J. Systemic delivery of peptides by the oral route: formulation and medicinal chemistry approaches. Adv. Drug Deliv. Rev. 157, 2\u201336 (2020).","journal-title":"Adv. Drug Deliv. Rev."},{"key":"135_CR180","doi-asserted-by":"publisher","first-page":"1571","DOI":"10.1007\/s40262-018-0649-2","volume":"57","author":"C Granhall","year":"2018","unstructured":"Granhall, C., Soendergaard, F. L., Thomsen, M. & Anderson, T. W. Pharmacokinetics, safety and tolerability of oral semaglutide in subjects with renal impairment. Clin. Pharmacokinet. 57, 1571\u20131580 (2018).","journal-title":"Clin. Pharmacokinet."},{"key":"135_CR181","doi-asserted-by":"publisher","first-page":"eaar7047","DOI":"10.1126\/scitranslmed.aar7047","volume":"10","author":"J Ahnfelt-Roenne","year":"2018","unstructured":"Ahnfelt-Roenne, J. et al. Transcellular stomach absorption of a derivatized glucagon-like peptide-1 receptor agonist. Sci. Transl. Med. 10, eaar7047 (2018).","journal-title":"Sci. Transl. Med."},{"key":"135_CR182","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1007\/s11102-016-0785-3","volume":"20","author":"NR Biermasz","year":"2017","unstructured":"Biermasz, N. R. New medical therapies on the horizon: oral octreotide. Pituitary 20, 149\u2013153 (2017).","journal-title":"Pituitary"},{"key":"135_CR183","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0059524","volume":"8","author":"R Eldor","year":"2013","unstructured":"Eldor, R., Arbit, E., Corcos, A. & Kidron, M. Glucose-reducing effect of the ORMD-0801 oral insulin preparation in patients with uncontrolled type 1 diabetes: a pilot study. PLoS ONE 8, e59524 (2013).","journal-title":"PLoS ONE"},{"key":"135_CR184","doi-asserted-by":"publisher","first-page":"1512","DOI":"10.1038\/s41591-019-0598-9","volume":"25","author":"A Abramson","year":"2019","unstructured":"Abramson, A. et al. A luminal unfolding microneedle injector for oral delivery of macromolecules. Nat. Med. 25, 1512\u20131518 (2019).","journal-title":"Nat. Med."},{"key":"135_CR185","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1126\/science.aau2277","volume":"363","author":"A Abramson","year":"2019","unstructured":"Abramson, A. et al. An ingestible self-orienting system for oral delivery of macromolecules. Science 363, 611\u2013615 (2019).","journal-title":"Science"},{"key":"135_CR186","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1016\/j.addr.2016.01.010","volume":"101","author":"E Moroz","year":"2016","unstructured":"Moroz, E., Matoori, S. & Leroux, J.-C. Oral delivery of macromolecular drugs: where we are after almost 100 years of attempts. Adv. Drug Deliv. Rev. 101, 108\u2013121 (2016).","journal-title":"Adv. Drug Deliv. Rev."},{"key":"135_CR187","doi-asserted-by":"publisher","first-page":"1972","DOI":"10.1021\/nn4057269","volume":"8","author":"DM Copolovici","year":"2014","unstructured":"Copolovici, D. M., Langel, K., Eriste, E. & Langel, U. Cell-penetrating peptides: design, synthesis, and applications. ACS Nano 8, 1972\u20131994 (2014).","journal-title":"ACS Nano"},{"key":"135_CR188","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/j.jconrel.2014.08.014","volume":"194","author":"N-Q Shi","year":"2014","unstructured":"Shi, N.-Q., Qi, X.-R., Xiang, B. & Zhang, Y. A survey on \u201cTrojan Horse\u201d peptides: opportunities, issues and controlled entry to \u201cTroy\u201d. J. Control. Rel. 194, 53\u201370 (2014).","journal-title":"J. Control. Rel."},{"key":"135_CR189","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1097\/MAO.0000000000002229","volume":"40","author":"H Staecker","year":"2019","unstructured":"Staecker, H. et al. Efficacy and safety of AM-111 in the treatment of acute unilateral sudden deafness - a double-blind, randomized, placebo-controlled phase 3 study. Otol. Neurotol. 40, 584\u2013594 (2019).","journal-title":"Otol. Neurotol."},{"key":"135_CR190","doi-asserted-by":"publisher","first-page":"878","DOI":"10.1016\/S0140-6736(20)30258-0","volume":"395","author":"MD Hill","year":"2020","unstructured":"Hill, M. D. et al. Efficacy and safety of nerinetide for the treatment of acute ischaemic stroke (ESCAPE-NA1): a multicentre, double-blind, randomised controlled trial. Lancet 395, 878\u2013887 (2020).","journal-title":"Lancet"},{"key":"135_CR191","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1016\/j.tips.2017.01.003","volume":"38","author":"G Guidotti","year":"2017","unstructured":"Guidotti, G., Brambilla, L. & Rossi, D. Cell-penetrating peptides: from basic research to clinics. Trends Pharmacol. Sci. 38, 406\u2013424 (2017).","journal-title":"Trends Pharmacol. Sci."},{"key":"135_CR192","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1016\/j.jocn.2016.04.012","volume":"33","author":"O Cohen-Inbar","year":"2016","unstructured":"Cohen-Inbar, O. & Zaaroor, M. Glioblastoma multiforme targeted therapy: the chlorotoxin story. J. Clin. Neurosci. 33, 52\u201358 (2016).","journal-title":"J. Clin. Neurosci."},{"key":"135_CR193","doi-asserted-by":"publisher","first-page":"1575","DOI":"10.1517\/14656566.9.9.1575","volume":"9","author":"JA Williams","year":"2008","unstructured":"Williams, J. A., Day, M. & Heavner, J. E. Ziconotide: an update and review. Expert. Opin. Pharmacother. 9, 1575\u20131583 (2008).","journal-title":"Expert. Opin. Pharmacother."},{"key":"135_CR194","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1038\/nrd1133","volume":"2","author":"BL Bray","year":"2003","unstructured":"Bray, B. L. Large-scale manufacture of peptide therapeutics by chemical synthesis. Nat. Rev. Drug Discov. 2, 587\u2013593 (2003).","journal-title":"Nat. Rev. Drug Discov."},{"key":"135_CR195","doi-asserted-by":"publisher","first-page":"361","DOI":"10.4155\/fmc.09.23","volume":"1","author":"AA Zompra","year":"2009","unstructured":"Zompra, A. A., Galanis, A. S., Werbitzky, O. & Albericio, F. Manufacturing peptides as active pharmaceutical ingredients. Future Med. Chem. 1, 361\u2013377 (2009).","journal-title":"Future Med. Chem."},{"key":"135_CR196","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1002\/bip.20734","volume":"88","author":"JP Mayer","year":"2007","unstructured":"Mayer, J. P., Zhang, F. & DiMarchi, R. D. Insulin structure and function. Biopolymers 88, 687\u2013713 (2007).","journal-title":"Biopolymers"},{"key":"135_CR197","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1016\/j.tibtech.2003.10.005","volume":"21","author":"S Lien","year":"2003","unstructured":"Lien, S. & Lowman, H. B. Therapeutic peptides. Trends Biotechnol. 21, 556\u2013562 (2003).","journal-title":"Trends Biotechnol."},{"key":"135_CR198","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1038\/nrd2094","volume":"6","author":"MN Pangalos","year":"2007","unstructured":"Pangalos, M. N., Schechter, L. E. & Hurko, O. Drug development for CNS disorders: strategies for balancing risk and reducing attrition. Nat. Rev. Drug Discov. 6, 521\u2013532 (2007).","journal-title":"Nat. Rev. Drug Discov."},{"key":"135_CR199","doi-asserted-by":"publisher","first-page":"3071","DOI":"10.2174\/138161210793292474","volume":"16","author":"CW Gruber","year":"2010","unstructured":"Gruber, C. W., Muttenthaler, M. & Freissmuth, M. Ligand-based peptide design and combinatorial peptide libraries to target G protein-coupled receptors. Curr. Pharm. Des. 16, 3071\u20133088 (2010).","journal-title":"Curr. Pharm. Des."},{"key":"135_CR200","doi-asserted-by":"publisher","first-page":"3670","DOI":"10.1016\/j.bbagen.2013.02.008","volume":"1830","author":"GM Cragg","year":"2013","unstructured":"Cragg, G. M. & Newman, D. J. Natural products: a continuing source of novel drug leads. Biochim. Biophys. Acta Gen. Subj. 1830, 3670\u20133695 (2013).","journal-title":"Biochim. Biophys. Acta Gen. Subj."},{"key":"135_CR201","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1038\/s41573-020-0062-z","volume":"19","author":"AP Davenport","year":"2020","unstructured":"Davenport, A. P., Scully, C. C. G., de Graaf, C., Brown, A. J. H. & Maguire, J. J. Advances in therapeutic peptides targeting G protein-coupled receptors. Nat. Rev. Drug Discov. 19, 389\u2013413 (2020).","journal-title":"Nat. Rev. Drug Discov."},{"key":"135_CR202","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1016\/j.ejmech.2015.01.014","volume":"94","author":"N Tsomaia","year":"2015","unstructured":"Tsomaia, N. Peptide therapeutics: targeting the undruggable space. Eur. J. Med. Chem. 94, 459\u2013470 (2015).","journal-title":"Eur. J. Med. Chem."},{"key":"135_CR203","doi-asserted-by":"publisher","first-page":"4695","DOI":"10.1021\/cr400698c","volume":"114","author":"L-G Milroy","year":"2014","unstructured":"Milroy, L.-G., Grossmann, T. N., Hennig, S., Brunsveld, L. & Ottmann, C. Modulators of protein-protein interactions. Chem. Rev. 114, 4695\u20134748 (2014).","journal-title":"Chem. Rev."},{"key":"135_CR204","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1016\/j.addr.2011.11.002","volume":"64","author":"JJ Lochhead","year":"2012","unstructured":"Lochhead, J. J. & Thorne, R. G. Intranasal delivery of biologics to the central nervous system. Adv. Drug Deliv. Rev. 64, 614\u2013628 (2012).","journal-title":"Adv. Drug Deliv. Rev."},{"key":"135_CR205","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1038\/nature03701","volume":"435","author":"M Kosfeld","year":"2005","unstructured":"Kosfeld, M., Heinrichs, M., Zak, P. J., Fischbacher, U. & Fehr, E. Oxytocin increases trust in humans. Nature 435, 673\u2013676 (2005).","journal-title":"Nature"},{"key":"135_CR206","doi-asserted-by":"publisher","first-page":"1445","DOI":"10.1016\/j.neubiorev.2013.04.012","volume":"37","author":"JG Veening","year":"2013","unstructured":"Veening, J. G. & Olivier, B. Intranasal administration of oxytocin: behavioral and clinical effects, a review. Neurosci. Biobehav. Rev. 37, 1445\u20131465 (2013).","journal-title":"Neurosci. Biobehav. Rev."},{"key":"135_CR207","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1016\/j.biopsych.2015.05.003","volume":"79","author":"G Leng","year":"2016","unstructured":"Leng, G. & Ludwig, M. Intranasal oxytocin: myths and delusions. Biol. Psychiatry 79, 243\u2013250 (2016).","journal-title":"Biol. Psychiatry"},{"key":"135_CR208","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1016\/j.biopsych.2015.06.016","volume":"79","author":"H Walum","year":"2016","unstructured":"Walum, H., Waldman, I. D. & Young, L. J. Statistical and methodological considerations for the interpretation of intranasal oxytocin studies. Biol. Psychiatry 79, 251\u2013257 (2016).","journal-title":"Biol. Psychiatry"},{"key":"135_CR209","doi-asserted-by":"publisher","first-page":"4690","DOI":"10.1039\/C6CS00076B","volume":"45","author":"B Oller-Salvia","year":"2016","unstructured":"Oller-Salvia, B., Sanchez-Navarro, M., Giralt, E. & Teixido, M. Blood-brain barrier shuttle peptides: an emerging paradigm for brain delivery. Chem. Soc. Rev. 45, 4690\u20134707 (2016).","journal-title":"Chem. Soc. Rev."},{"key":"135_CR210","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1016\/j.addr.2011.11.010","volume":"64","author":"Y Chen","year":"2012","unstructured":"Chen, Y. & Liu, L. Modern methods for delivery of drugs across the blood-brain barrier. Adv. Drug Deliv. Rev. 64, 640\u2013665 (2012).","journal-title":"Adv. Drug Deliv. Rev."},{"key":"135_CR211","doi-asserted-by":"publisher","first-page":"2927","DOI":"10.1113\/jphysiol.2014.270850","volume":"592","author":"GJ Dockray","year":"2014","unstructured":"Dockray, G. J. Gastrointestinal hormones and the dialogue between gut and brain. J. Physiol. 592, 2927\u20132941 (2014).","journal-title":"J. Physiol."},{"key":"135_CR212","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1021\/mp400680d","volume":"11","author":"A Lalatsa","year":"2014","unstructured":"Lalatsa, A., Schatzlein, A. G. & Uchegbu, I. F. Strategies to deliver peptide drugs to the brain. Mol. Pharm. 11, 1081\u20131093 (2014).","journal-title":"Mol. Pharm."},{"key":"135_CR213","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1146\/annurev-pharmtox-010814-124852","volume":"55","author":"JM Lajoie","year":"2015","unstructured":"Lajoie, J. M. & Shusta, E. V. Targeting receptor-mediated transport for delivery of biologics across the blood-brain barrier. Annu. Rev. Pharmacol. Toxicol. 55, 613\u2013631 (2015).","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"key":"135_CR214","doi-asserted-by":"publisher","first-page":"6553","DOI":"10.1039\/C7CS00536A","volume":"46","author":"H Acar","year":"2017","unstructured":"Acar, H., Ting, J. M., Srivastava, S., La Belle, J. L. & Tirrell, M. V. Molecular engineering solutions for therapeutic peptide delivery. Chem. Soc. Rev. 46, 6553\u20136569 (2017).","journal-title":"Chem. Soc. Rev."},{"key":"135_CR215","doi-asserted-by":"publisher","first-page":"481","DOI":"10.7150\/thno.4024","volume":"2","author":"M Fani","year":"2012","unstructured":"Fani, M., Maecke, H. R. & Okarvi, S. M. Radiolabeled peptides: valuable tools for the detection and treatment of cancer. Theranostics 2, 481\u2013501 (2012).","journal-title":"Theranostics"},{"key":"135_CR216","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1093\/intimm\/dxw027","volume":"28","author":"M Hirayama","year":"2016","unstructured":"Hirayama, M. & Nishimura, Y. The present status and future prospects of peptide-based cancer vaccines. Int. Immunol. 28, 319\u2013328 (2016).","journal-title":"Int. Immunol."},{"key":"135_CR217","doi-asserted-by":"publisher","first-page":"6011","DOI":"10.7150\/thno.38742","volume":"10","author":"X Chen","year":"2020","unstructured":"Chen, X., Yang, J., Wang, L. & Liu, B. Personalized neoantigen vaccination with synthetic long peptides: recent advances and future perspectives. Theranostics 10, 6011\u20136023 (2020).","journal-title":"Theranostics"},{"key":"135_CR218","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1039\/C5SC03892H","volume":"7","author":"M Skwarczynski","year":"2016","unstructured":"Skwarczynski, M. & Toth, I. Peptide-based synthetic vaccines. Chem. Sci. 7, 842\u2013854 (2016).","journal-title":"Chem. Sci."},{"key":"135_CR219","doi-asserted-by":"publisher","first-page":"3210","DOI":"10.1021\/acs.chemrev.9b00472","volume":"120","author":"RJ Malonis","year":"2020","unstructured":"Malonis, R. J., Lai, J. R. & Vergnolle, O. Peptide-based vaccines: current progress and future challenges. Chem. Rev. 120, 3210\u20133229 (2020).","journal-title":"Chem. Rev."},{"key":"135_CR220","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1124\/jpet.112.199430","volume":"344","author":"RW Busby","year":"2013","unstructured":"Busby, R. W. et al. Pharmacologic properties, metabolism, and disposition of linaclotide, a novel therapeutic peptide approved for the treatment of irritable bowel syndrome with constipation and chronic idiopathic constipation. J. Pharmacol. Exp. Ther. 344, 196\u2013206 (2013).","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"135_CR221","doi-asserted-by":"publisher","first-page":"1551","DOI":"10.1038\/nbt1267","volume":"24","author":"REW Hancock","year":"2006","unstructured":"Hancock, R. E. W. & Sahl, H.-G. Antimicrobial and host-defense peptides as new anti-infective therapeutic strategies. Nat. Biotechnol. 24, 1551\u20131557 (2006).","journal-title":"Nat. Biotechnol."},{"key":"135_CR222","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s12275-017-6452-1","volume":"55","author":"H-K Kang","year":"2017","unstructured":"Kang, H.-K., Kim, C., Seo, C. H. & Park, Y. The therapeutic applications of antimicrobial peptides (AMPs): a patent review. J. Microbiol. 55, 1\u201312 (2017).","journal-title":"J. Microbiol."},{"key":"135_CR223","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1046\/j.1467-2494.2002.00153.x","volume":"24","author":"C Blanes-Mira","year":"2002","unstructured":"Blanes-Mira, C. et al. A synthetic hexapeptide (Argireline) with antiwrinkle activity. Int. J. Cosmet. Sci. 24, 303\u2013310 (2002).","journal-title":"Int. J. Cosmet. Sci."},{"key":"135_CR224","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1111\/j.1467-2494.2005.00261.x","volume":"27","author":"LR Robinson","year":"2005","unstructured":"Robinson, L. R. et al. Topical palmitoyl pentapeptide provides improvement in photoaged human facial skin. Int. J. Cosmet. Sci. 27, 155\u2013160 (2005).","journal-title":"Int. J. Cosmet. Sci."},{"key":"135_CR225","doi-asserted-by":"publisher","first-page":"969","DOI":"10.1163\/156856208784909435","volume":"19","author":"L Pickart","year":"2008","unstructured":"Pickart, L. The human tri-peptide glycine-histidine-lysine and tissue remodeling. J. Biomater. Sci. Polym. Ed. 19, 969\u2013988 (2008).","journal-title":"J. Biomater. Sci. Polym. Ed."},{"key":"135_CR226","doi-asserted-by":"publisher","first-page":"3115","DOI":"10.1021\/ja01641a004","volume":"76","author":"V Du Vigneaud","year":"1954","unstructured":"Du Vigneaud, V., Ressler, C., Swan, J. M., Roberts, C. W. & Katsoyannis, P. G. The synthesis of oxytocin. J. Am. Chem. Soc. 76, 3115\u20133121 (1954).","journal-title":"J. Am. Chem. Soc."},{"key":"135_CR227","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1016\/S0021-9258(18)49238-1","volume":"205","author":"V Du Vigneaud","year":"1953","unstructured":"Du Vigneaud, V., Ressler, C. & Trippett, S. The sequence of amino acids in oxytocin, with a proposal for the structure of oxytocin. J. Biol. Chem. 205, 949\u2013957 (1953).","journal-title":"J. Biol. Chem."},{"key":"135_CR228","unstructured":"Global Information Inc. Global Peptide Therapeutics Sales Market Report 2018. QYResearch, 387893 (2018)."},{"key":"135_CR229","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1016\/j.jns.2017.03.030","volume":"376","author":"B Weinstock-Guttman","year":"2017","unstructured":"Weinstock-Guttman, B., Nair, K. V., Glajch, J. L., Ganguly, T. C. & Kantor, D. Two decades of glatiramer acetate: from initial discovery to the current development of generics. J. Neurol. Sci. 376, 255\u2013259 (2017).","journal-title":"J. Neurol. Sci."},{"key":"135_CR230","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1002\/eji.1830010406","volume":"1","author":"D Teitelbaum","year":"1971","unstructured":"Teitelbaum, D., Meshorer, A., Hirshfeld, T., Arnon, R. & Sela, M. Suppression of experimental allergic encephalomyelitis by a synthetic polypeptide. Eur. J. Immunol. 1, 242\u2013248 (1971).","journal-title":"Eur. J. Immunol."},{"key":"135_CR231","doi-asserted-by":"publisher","first-page":"1268","DOI":"10.1212\/WNL.45.7.1268","volume":"45","author":"KP Johnson","year":"1995","unstructured":"Johnson, K. P. et al. Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. Neurology 45, 1268\u20131276 (1995).","journal-title":"Neurology"},{"key":"135_CR232","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1016\/j.autrev.2012.09.005","volume":"12","author":"R Aharoni","year":"2013","unstructured":"Aharoni, R. The mechanism of action of glatiramer acetate in multiple sclerosis and beyond. Autoimmun. Rev. 12, 543\u2013553 (2013).","journal-title":"Autoimmun. Rev."},{"key":"135_CR233","doi-asserted-by":"publisher","first-page":"401","DOI":"10.2165\/11588120-000000000-00000","volume":"25","author":"PH Lalive","year":"2011","unstructured":"Lalive, P. H. et al. Glatiramer acetate in the treatment of multiple sclerosis: emerging concepts regarding its mechanism of action. CNS Drugs 25, 401\u2013414 (2011).","journal-title":"CNS Drugs"},{"key":"135_CR234","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1038\/nrd1331","volume":"3","author":"T Matthews","year":"2004","unstructured":"Matthews, T. et al. Enfuvirtide: the first therapy to inhibit the entry of HIV-1 into host CD4 lymphocytes. Nat. Rev. Drug Discov. 3, 215\u2013225 (2004).","journal-title":"Nat. Rev. Drug Discov."},{"key":"135_CR235","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.1089\/aid.1993.9.1051","volume":"9","author":"C Wild","year":"1993","unstructured":"Wild, C., Greenwell, T. & Matthews, T. A synthetic peptide from HIV-1 gp41 is a potent inhibitor of virus-mediated cell-cell fusion. AIDS Res. Hum. Retroviruses 9, 1051\u20131053 (1993).","journal-title":"AIDS Res. Hum. Retroviruses"},{"key":"135_CR236","doi-asserted-by":"publisher","first-page":"29","DOI":"10.2174\/1389201043489620","volume":"5","author":"T Bruckdorfer","year":"2004","unstructured":"Bruckdorfer, T., Marder, O. & Albericio, F. From production of peptides in milligram amounts for research to multi-tons quantities for drugs of the future. Curr. Pharm. Biotechnol. 5, 29\u201343 (2004).","journal-title":"Curr. Pharm. Biotechnol."},{"key":"135_CR237","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/j.cbpa.2016.08.022","volume":"34","author":"JR Kintzing","year":"2016","unstructured":"Kintzing, J. R. & Cochran, J. R. Engineered knottin peptides as diagnostics, therapeutics, and drug delivery vehicles. Curr. Opin. Chem. Biol. 34, 143\u2013150 (2016).","journal-title":"Curr. Opin. Chem. Biol."},{"key":"135_CR238","doi-asserted-by":"publisher","first-page":"1833","DOI":"10.1002\/pro.5560031022","volume":"3","author":"PK Pallaghy","year":"1994","unstructured":"Pallaghy, P. K., Nielsen, K. J., Craik, D. J. & Norton, R. A common structural motif incorporating a cystine knot and a triple-stranded \u03b2-sheet in toxic and inhibitory polypeptides. Protein Sci. 3, 1833\u20131836 (1994).","journal-title":"Protein Sci."},{"key":"135_CR239","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1002\/bies.201500165","volume":"38","author":"EAB Undheim","year":"2016","unstructured":"Undheim, E. A. B., Mobli, M. & King, G. F. Toxin structures as evolutionary tools: using conserved 3D folds to study the evolution of rapidly evolving peptides. Bioessays 38, 539\u2013548 (2016).","journal-title":"Bioessays"},{"key":"135_CR240","doi-asserted-by":"publisher","first-page":"2299","DOI":"10.1021\/jm501765v","volume":"58","author":"JK Murray","year":"2015","unstructured":"Murray, J. K. et al. Engineering potent and selective analogues of GpTx-1, a tarantula venom peptide antagonist of the Nav1.7 sodium channel. J. Med. Chem. 58, 2299\u20132314 (2015).","journal-title":"J. Med. Chem."},{"key":"135_CR241","doi-asserted-by":"publisher","DOI":"10.1038\/srep39662","volume":"7","author":"M Flinspach","year":"2017","unstructured":"Flinspach, M. et al. Insensitivity to pain induced by a potent selective closed-state Nav1.7 inhibitor. Sci. Rep. 7, 39662 (2017).","journal-title":"Sci. Rep."},{"key":"135_CR242","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/j.peptides.2013.03.011","volume":"44","author":"JD Revell","year":"2013","unstructured":"Revell, J. D. et al. Potency optimization of Huwentoxin-IV on hNav1.7: a neurotoxin TTX-S sodium-channel antagonist from the venom of the Chinese bird-eating spider Selenocosmia huwena. Peptides 44, 40\u201346 (2013).","journal-title":"Peptides"},{"key":"135_CR243","doi-asserted-by":"publisher","first-page":"1476","DOI":"10.1124\/mol.108.047670","volume":"74","author":"WA Schmalhofer","year":"2008","unstructured":"Schmalhofer, W. A. et al. ProTx-II, a selective inhibitor of Nav1.7 sodium channels, blocks action potential propagation in nociceptors. Mol. Pharmacol. 74, 1476\u20131484 (2008).","journal-title":"Mol. Pharmacol."},{"key":"135_CR244","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1038\/nrd.2016.230","volume":"16","author":"R Santos","year":"2017","unstructured":"Santos, R. et al. A comprehensive map of molecular drug targets. Nat. Rev. Drug Discov. 16, 19\u201334 (2017).","journal-title":"Nat. Rev. Drug Discov."},{"key":"135_CR245","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1124\/pr.57.4.13","volume":"57","author":"FH Yu","year":"2005","unstructured":"Yu, F. H., Yarov-Yarovoy, V., Gutman, G. A. & Catterall, W. A. Overview of molecular relationships in the voltage-gated ion channel superfamily. Pharmacol. Rev. 57, 387\u2013395 (2005).","journal-title":"Pharmacol. Rev."},{"key":"135_CR246","doi-asserted-by":"publisher","first-page":"2577","DOI":"10.1113\/jphysiol.2011.224204","volume":"590","author":"WA Catterall","year":"2012","unstructured":"Catterall, W. A. Voltage-gated sodium channels at 60: structure, function and pathophysiology. J. Physiol. 590, 2577\u20132589 (2012).","journal-title":"J. Physiol."},{"key":"135_CR247","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1085\/jgp.201511492","volume":"147","author":"CA Ahern","year":"2016","unstructured":"Ahern, C. A., Payandeh, J., Bosmans, F. & Chanda, B. The hitchhiker\u2019s guide to the voltage-gated sodium channel galaxy. J. Gen. Physiol. 147, 1\u201324 (2016).","journal-title":"J. Gen. Physiol."},{"key":"135_CR248","doi-asserted-by":"publisher","first-page":"1309","DOI":"10.1126\/science.aaw2999","volume":"363","author":"X Pan","year":"2019","unstructured":"Pan, X. et al. Molecular basis for pore blockade of human Na+ channel Nav1.2 by the \u03bc-conotoxin KIIIA. Science 363, 1309\u20131313 (2019).","journal-title":"Science"},{"key":"135_CR249","doi-asserted-by":"publisher","first-page":"eaau2596","DOI":"10.1126\/science.aau2596","volume":"362","author":"H Shen","year":"2018","unstructured":"Shen, H. et al. Structural basis for the modulation of voltage-gated sodium channels by animal toxins. Science 362, eaau2596 (2018).","journal-title":"Science"}],"container-title":["Nature Reviews Drug Discovery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41573-020-00135-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41573-020-00135-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41573-020-00135-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,20]],"date-time":"2023-10-20T00:48:52Z","timestamp":1697762932000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41573-020-00135-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2,3]]},"references-count":249,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2021,4]]}},"alternative-id":["135"],"URL":"https:\/\/doi.org\/10.1038\/s41573-020-00135-8","relation":{},"ISSN":["1474-1776","1474-1784"],"issn-type":[{"value":"1474-1776","type":"print"},{"value":"1474-1784","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,2,3]]},"assertion":[{"value":"11 December 2020","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 February 2021","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}